The latest price target for ABVC BioPharma (NASDAQ:ABVC) was reported by Maxim Group on November 16, 2022. The analyst firm set a price target for $0.00 expecting ABVC to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for ABVC BioPharma (NASDAQ:ABVC) was provided by Maxim Group, and ABVC BioPharma downgraded their hold rating.

There is no last upgrade for ABVC BioPharma

The last downgrade for ABVC BioPharma Inc happened on November 16, 2022 when Maxim Group changed their price target from N/A to N/A for ABVC BioPharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ABVC BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ABVC BioPharma was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.

While ratings are subjective and will change, the latest ABVC BioPharma (ABVC) rating was a downgraded with a price target of $0.00 to $0.00. The current price ABVC BioPharma (ABVC) is trading at is $0.71, which is out of the analyst’s predicted range.